In the surgical business, Alcon (ALC) faces a mix of competitors, ranging from large manufacturers with multiple business lines to small manufacturers.

Beyond analysts' top -and-bottom-line estimates for Alcon (ALC), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter...

In the surgical business, Alcon (ALC) faces a mix of competitors, ranging from large manufacturers with multiple business lines to small manufacturers.

Investors with an interest in Medical - Instruments stocks have likely encountered both Alcon (ALC) and Idexx Laboratories (IDXX). But which of these two stocks presents investors with the better v...

Alcon (ALC) Q3 revenues increase year over year, driven by strength in Surgical and Vision Care segments.

While the top- and bottom-line numbers for Alcon (ALC) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compa...

Alcon Inc. shares ALC, +4.04% dropped more than 4% premarket on Wednesday after the eye care company on Tuesday reported third-quarter revenues below analysts' expectations.

Alcon (ALC) continues gaining from the company's diverse portfolio, incremental innovation, and new product launches.

Within Vision Care, Alcon (ALC) is registering solid growth, banking on strong sales of its contact lenses and ocular health products.

Alcon (ALC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising e...

At this stage, it is prudent to invest in low-beta stocks with a favorable Zacks Rank like ALC, RDY and ANIK, as these will be less volatile than the broader market.

Here is how Alcon (ALC) and Molina (MOH) have performed compared to their sector so far this year.

Investors continue to be optimistic about Alcon (ALC) on the impressive performance of its portfolio.

Alcon's (ALC) Surgical business continues to gain from diverse portfolio and incremental innovation.

Alcon's (ALC) Vivity Registry study data highlights the lens's versatility in treating a wide range of patients.